The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 348:1599 April 17, 2003 Number 16
NextNext

Natalizumab for Active Crohn's Disease

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Ghosh, S.
-PubMed Citation
To the Editor: In the study by Ghosh et al. (Jan. 2 issue),1 a regimen of two infusions of natalizumab at a dose of 6 mg per kilogram of body weight was associated with higher remission rates than was placebo at several intervals, except at week 6 (the primary end point). The failure to demonstrate a difference may be due in part to chance and to the use of a small study sample. Randomization is supposed to ensure equal distribution of base-line characteristics that may confound a clinical trial. However, in this study, the randomization process assigned 63 patients to . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.